{
  "schema_version": 1,
  "kind": "drug_profile",
  "generic": "perindopril",
  "review_status": "reviewed",
  "origin": "openfda",
  "sections": {
    "adult": [
      {
        "text": "Hypertension The recommended initial dose is 4 mg once a day.",
        "source": "US FDA label for perindopril (Perindopril Erbumine), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/perindopril.json",
        "verbatim": true
      },
      {
        "text": "The dosage may be titrated upward until blood pressure, when measured just before the next dose, is controlled or to a maximum of 16 mg per day.",
        "source": "US FDA label for perindopril (Perindopril Erbumine), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/perindopril.json",
        "verbatim": true
      },
      {
        "text": "(2.1) Stable Coronary Artery Disease Perindopril erbumine tablets should be given at an initial dose of 4 mg once daily for 2 weeks, and then increased, as tolerated, to a maintenance dose of 8 mg once daily.",
        "source": "US FDA label for perindopril (Perindopril Erbumine), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/perindopril.json",
        "verbatim": true
      }
    ],
    "child": [
      {
        "text": "Neonates With a History of in utero Exposure to Perindopril Erbumine: If oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function.",
        "source": "US FDA label for perindopril (Perindopril Erbumine), section 'pediatric use', retrieved 2026-08-29",
        "cached_file": "labels/perindopril.json",
        "verbatim": true
      }
    ],
    "renal": [
      {
        "text": "In elderly patients (greater than 70 years), perindopril erbumine tablets should be given as a 2 mg dose once daily in the first week, followed by 4 mg once daily in the second week and 8 mg once daily for maintenance dose if tolerated. 2.3 Dose Adjustment in Renal Impairment and Dialysis Perindoprilat elimination is decreased in renally impaired patients.",
        "source": "US FDA label for perindopril (Perindopril Erbumine), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/perindopril.json",
        "verbatim": true
      },
      {
        "text": "Perindopril erbumine tablets are not recommended in patients with creatinine clearance <30 mL/min.",
        "source": "US FDA label for perindopril (Perindopril Erbumine), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/perindopril.json",
        "verbatim": true
      },
      {
        "text": "During dialysis, perindopril is removed with the same clearance as in patients with normal renal function.",
        "source": "US FDA label for perindopril (Perindopril Erbumine), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/perindopril.json",
        "verbatim": true
      }
    ],
    "hepatic": [
      {
        "text": "Experience with perindopril erbumine in elderly patients at daily doses exceeding 8 mg is limited. 8.6 Renal Impairment Dosage adjustment may be necessary in renally impaired patients [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . 8.7 Hepatic Impairment The bioavailability of perindoprilat is increased in patients with impaired hepatic function [see Clinical Pharmacology (12.3) ] .",
        "source": "US FDA label for perindopril (Perindopril Erbumine), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/perindopril.json",
        "verbatim": true
      }
    ],
    "pregnancy": [
      {
        "text": "Pregnancy Category D [see Boxed Warning and Warnings and Precautions (5.4) ] .",
        "source": "US FDA label for perindopril (Perindopril Erbumine), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/perindopril.json",
        "verbatim": true
      },
      {
        "text": "Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.",
        "source": "US FDA label for perindopril (Perindopril Erbumine), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/perindopril.json",
        "verbatim": true
      },
      {
        "text": "Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations.",
        "source": "US FDA label for perindopril (Perindopril Erbumine), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/perindopril.json",
        "verbatim": true
      }
    ],
    "lactation": [
      {
        "text": "Milk of lactating rats contained radioactivity following administration of 14 C-perindopril.",
        "source": "US FDA label for perindopril (Perindopril Erbumine), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/perindopril.json",
        "verbatim": true
      },
      {
        "text": "It is not known whether perindopril is secreted in human milk.",
        "source": "US FDA label for perindopril (Perindopril Erbumine), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/perindopril.json",
        "verbatim": true
      },
      {
        "text": "Because many drugs are secreted in human milk, caution should be exercised when perindopril erbumine is given to nursing mothers.",
        "source": "US FDA label for perindopril (Perindopril Erbumine), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/perindopril.json",
        "verbatim": true
      }
    ]
  }
}